PVALB and schizophrenia: Furthermore, Nakamura et al. (120) reported that the oral administration of T-817MA ameliorated behavioral, histological, and neurophysiological changes, such as deficits in prepulse inhibition, reduced levels of parvalbumin-immunoreactive neurons in the medial prefrontal cortex, hippocampus, and amygdala, and a deficit in the auditory phase-locked gamma oscillation in a mouse model of schizophrenia.